{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,6]],"date-time":"2026-11-06T17:38:35Z","timestamp":1793986715668,"version":"4.8.0"},"reference-count":38,"publisher":"Frontiers Media SA","license":[{"start":{"date-parts":[[2026,9,14]],"date-time":"2026-09-14T00:00:00Z","timestamp":1789344000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["frontiersin.org"],"crossmark-restriction":true},"short-container-title":["Front. Immunol."],"abstract":"<jats:p>Bispecific antibodies targeting two inflammatory pathways are entering respiratory medicine at an unprecedented pace. TSLP\/IL-13 bispecifics have progressed into mid-to-late-stage clinical development, with two distinct molecules (lunsekimig and CM512) in Phase II\/III and Phase II trials, respectively. Preclinical and early clinical signals indicate that alarmin blockade may extend beyond classical type 2 immunity, offering therapeutic potential in mixed and non-type 2 inflammatory phenotypes. Yet this molecular acceleration risks outpacing our capacity to deploy these agents rationally. No biomarker-guided framework currently exists to determine which patients require dual-pathway versus single-pathway blockade, or which target pair best matches a given patient\u2019s inflammatory endotype. The central clinical tension is whether the incremental benefit of dual-pathway neutralization justifies any increase in immunosuppressive risk. In this Perspective, we argue that the bispecific antibody race may deliver more molecules than necessary unless the field simultaneously builds biomarker-guided matching frameworks. Limited clinical support, drawn mainly from single-target agents such as tezepelumab (efficacy across eosinophil strata) and itepekimab (benefit in former smokers with COPD independent of eosinophils), together with biological rationale, suggests that alarmin blockade may hold promise in mixed and non-type 2 phenotypes; dedicated dual-alarmin trials in these populations remain needed.<\/jats:p>","DOI":"10.3389\/fimmu.2026.1906783","type":"journal-article","created":{"date-parts":[[2026,9,14]],"date-time":"2026-09-14T04:35:03Z","timestamp":1789360503000},"update-policy":"https:\/\/doi.org\/10.3389\/crossmark-policy","source":"Crossref","is-referenced-by-count":1,"title":["The dawn of the dual-target era in respiratory disease: promise, pitfalls, and a roadmap for bispecific antibodies"],"prefix":"10.3389","volume":"17","author":[{"given":"Yikun","family":"Cheng","sequence":"first","affiliation":[{"name":"First Affiliated Hospital of Anhui University of Chinese Medicine","place":["Hefei, China"]},{"name":"Anhui University of Chinese Medicine","place":["Hefei, China"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jian","family":"Ding","sequence":"additional","affiliation":[{"name":"First Affiliated Hospital of Anhui University of Chinese Medicine","place":["Hefei, China"]},{"name":"Anhui University of Chinese Medicine","place":["Hefei, China"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zegeng","family":"Li","sequence":"additional","affiliation":[{"name":"First Affiliated Hospital of Anhui University of Chinese Medicine","place":["Hefei, China"]},{"name":"Institute of Respiratory Disease Prevention and Treatment, Anhui Academy of Chinese Medicine","place":["Hefei, China"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jiabing","family":"Tong","sequence":"additional","affiliation":[{"name":"First Affiliated Hospital of Anhui University of Chinese Medicine","place":["Hefei, China"]},{"name":"Anhui University of Chinese Medicine","place":["Hefei, China"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Cheng","family":"Yang","sequence":"additional","affiliation":[{"name":"First Affiliated Hospital of Anhui University of Chinese Medicine","place":["Hefei, China"]}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1965","published-online":{"date-parts":[[2026,9,14]]},"reference":[{"key":"B1","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2026.1811041","article-title":"First-in-human, phase 1 study of CM512, a TSLP\/IL-13 bispecific antibody, in healthy volunteers: safety, tolerability, pharmacokinetics, pharmacodynamics, and immunogenicity","volume":"17","author":"Cheng","year":"2026","journal-title":"Front Immunol"},{"key":"B2","article-title":"A randomized, double-blind, placebo-controlled phase II clinical study evaluating CM512 injection in subjects with moderate-to-severe chronic obstructive pulmonary disease","year":"2025"},{"key":"B3","doi-asserted-by":"publisher","DOI":"10.1164\/ajrccm.2025.211.abstracts.a1302","article-title":"BBT002: A novel tetravalent bispecific antibody targeting IL4Ra and IL5 for enhanced asthma therapy","volume":"211","author":"Ho","year":"2025","journal-title":"Am J Respir Crit Care Med"},{"key":"B4","doi-asserted-by":"publisher","first-page":"1185","DOI":"10.1016\/j.jaci.2018.06.002","article-title":"A bispecific antibody strategy to target multiple type 2 cytokines in asthma","volume":"142","author":"Godar","year":"2018","journal-title":"J\u00a0Allergy Clin Immunol"},{"key":"B5","doi-asserted-by":"publisher","first-page":"19","DOI":"10.1016\/j.bbrc.2018.08.064","article-title":"Design and characterization of Zweimab and Doppelmab, high affinity dual antagonistic anti-TSLP\/IL13 bispecific antibodies","volume":"504","author":"Venkataramani","year":"2018","journal-title":"Biochem Biophys Res Commun"},{"key":"B6","doi-asserted-by":"publisher","first-page":"705","DOI":"10.1016\/j.jaci.2016.08.026","article-title":"Combined blockade of the IL-13 and IL-33 pathways leads to a greater inhibition of type 2 inflammation over inhibition of either pathway alone","volume":"139","author":"Ramirez-Carrozzi","year":"2017","journal-title":"J Allergy Clin Immunol"},{"key":"B7","doi-asserted-by":"publisher","DOI":"10.1111\/all.14196","article-title":"TSLP and IL-33 reciprocally promote each other's lung protein expression and ILC2 receptor expression to enhance innate type-2 airway inflammation","volume":"75","author":"Toki","year":"2020","journal-title":"Allergy"},{"key":"B8","doi-asserted-by":"publisher","DOI":"10.3389\/falgy.2025.1700060","article-title":"Potential of alarmin-targeted bispecific and combination therapies in airway disease","volume":"6","author":"Komori","year":"2025","journal-title":"Front Allergy"},{"key":"B9","doi-asserted-by":"publisher","DOI":"10.1183\/13993003.congress-2025.pa4770","article-title":"Late breaking abstract - Bispecific antibody targeting IL33 and TSLP for treating asthma and COPD","volume":"66","author":"Zhu","year":"2025","journal-title":"Eur Respir J"},{"key":"B10","doi-asserted-by":"publisher","DOI":"10.1056\/nejmoa1704064","article-title":"Tezepelumab in adults with uncontrolled asthma","volume":"377","author":"Corren","year":"2017","journal-title":"N Engl J Med"},{"key":"B11","doi-asserted-by":"publisher","DOI":"10.1056\/nejmoa2034975","article-title":"Tezepelumab in adults and adolescents with severe, uncontrolled asthma","volume":"384","author":"Menzies-Gow","year":"2021","journal-title":"N Engl J Med"},{"key":"B12","doi-asserted-by":"publisher","DOI":"10.1164\/ajrccm.2025.211.abstracts.a3446","article-title":"ZW1528, a bispecific antibody targeting IL-4R\u03b1 and IL-33, potently inhibits key mediators of airway inflammation","volume":"211","author":"Poffenberger","year":"2025","journal-title":"Am J Respir Crit Care Med"},{"key":"B13","doi-asserted-by":"publisher","DOI":"10.1183\/13993003.congress-2025.pa4587","article-title":"Late breaking abstract - ZW1528: A dual-targeting bispecific antibody to broadly suppress airway inflammation by inhibiting IL-4Ra and IL-33 pathways","volume":"66","author":"Hardman","year":"2025","journal-title":"Eur Respir J"},{"key":"B14","article-title":"Efficacy, safety, and tolerability study of lunsekimig compared with placebo in adult participants with inadequately controlled chronic obstructive pulmonary disease (COPD), characterized by an eosinophilic phenotype (THESEUS)","year":"2025"},{"key":"B15","article-title":"Efficacy, safety, and tolerability study of lunsekimig compared with placebo in adult participants with inadequately controlled chronic obstructive pulmonary disease (COPD) characterized by an eosinophilic phenotype (PERSEPHONE)","year":"2025"},{"key":"B16","doi-asserted-by":"publisher","first-page":"2401461","DOI":"10.1183\/13993003.01461-2024","article-title":"A proof-of-mechanism trial in asthma with lunsekimig, a bispecific NANOBODY molecule","volume":"65","author":"Deiteren","year":"2025","journal-title":"Eur Respir J"},{"key":"B17","doi-asserted-by":"publisher","DOI":"10.1016\/j.jaci.2006.07.041","article-title":"Reversal of airway inflammation and remodeling in asthma by a bispecific antibody fragment linking CCR3 to CD300a","volume":"118","author":"Munitz","year":"2006","journal-title":"J Allergy Clin Immunol"},{"key":"B18","doi-asserted-by":"publisher","DOI":"10.1002\/jlb.2mr1117-433r","article-title":"CD300 family receptors regulate eosinophil survival, chemotaxis, and effector functions","volume":"104","author":"Rozenberg","year":"2018","journal-title":"J Leukoc Biol"},{"key":"B19","doi-asserted-by":"publisher","first-page":"157","DOI":"10.1186\/s12931-026-03597-3","article-title":"Multidomain clinical and biological remission with tezepelumab in severe asthma: a 12-month multicentre real-world study","volume":"27","author":"Garc\u00eda-Rivero","year":"2026","journal-title":"Respir Res"},{"key":"B20","doi-asserted-by":"publisher","DOI":"10.1056\/nejmoa1804092","article-title":"Dupilumab efficacy and safety in moderate-to-severe uncontrolled asthma","volume":"378","author":"Castro","year":"2018","journal-title":"N Engl J Med"},{"key":"B21","doi-asserted-by":"publisher","first-page":"56","DOI":"10.1016\/j.chest.2025.01.029","article-title":"Effect of dupilumab on health-related quality of life and respiratory symptoms in patients with COPD and type 2 inflammation: BOREAS and NOTUS","volume":"168","author":"Bhatt","year":"2025","journal-title":"Chest"},{"key":"B22","doi-asserted-by":"publisher","first-page":"489","DOI":"10.1007\/s40264-017-0636-9","article-title":"Potential risks related to modulating interleukin-13 and interleukin-4 signalling: A systematic review","volume":"41","author":"Braddock","year":"2018","journal-title":"Drug Saf"},{"key":"B23","doi-asserted-by":"publisher","DOI":"10.1172\/jci.insight.123919","article-title":"IL-33-mediated IL-13 secretion by ST2+ Tregs controls inflammation after lung injury","volume":"4","author":"Liu","year":"2019","journal-title":"JCI Insight"},{"key":"B24","doi-asserted-by":"publisher","DOI":"10.1016\/j.rmed.2023.107414","article-title":"Biologics in severe asthma: A pragmatic approach for choosing the right treatment for the right patient","volume":"218","author":"Rogers","year":"2023","journal-title":"Respir Med"},{"key":"B25","doi-asserted-by":"publisher","DOI":"10.1183\/13993003.01359-2015","article-title":"Treatable traits: toward precision medicine of chronic airway diseases","volume":"47","author":"Agusti","year":"2016","journal-title":"Eur Respir J"},{"key":"B26","doi-asserted-by":"publisher","DOI":"10.1007\/s40259-025-00744-y","article-title":"Biological therapies in chronic obstructive pulmonary disease: New directions in personalised respiratory medicine","volume":"39","author":"Mappin-Kasirer","year":"2025","journal-title":"BioDrugs"},{"key":"B27","doi-asserted-by":"publisher","DOI":"10.1056\/nejmoa2413181","article-title":"Mepolizumab to prevent exacerbations of COPD with an eosinophilic phenotype","volume":"392","author":"Sciurba","year":"2025","journal-title":"N Engl J Med"},{"key":"B28","doi-asserted-by":"publisher","DOI":"10.2147\/copd.s550144","article-title":"Multi-criteria decision analysis of biologics in chronic obstructive pulmonary disease","volume":"20","author":"Matera","year":"2025","journal-title":"Int J Chron Obstruct Pulmon Dis"},{"key":"B29","doi-asserted-by":"publisher","DOI":"10.1021\/acsomega.5c07657","article-title":"Multiomics and machine learning reveal distinct immune-metabolic signatures and diagnostic biomarkers for asthma inflammatory endotypes","volume":"10","author":"Liu","year":"2025","journal-title":"ACS Omega"},{"key":"B30","doi-asserted-by":"publisher","DOI":"10.1016\/j.chest.2025.07.3082","article-title":"S174\u2005Reduction of exacerbations according to type 2 inflammatory biomarkers with dupilumab treatment in patients with chronic obstructive pulmonary disease","volume":"80","author":"Couillard","year":"2025","journal-title":"Thorax"},{"key":"B31","doi-asserted-by":"publisher","DOI":"10.1016\/j.resinv.2025.04.022","article-title":"Switching to tezepelumab from other biologics in patients with severe asthma: a retrospective study","volume":"63","author":"Sumi","year":"2025","journal-title":"Respir Investig"},{"key":"B32","doi-asserted-by":"publisher","DOI":"10.1016\/j.rmed.2025.108343","article-title":"Efficacy of dupilumab and mepolizumab in eosinophilic COPD: insights from phase 3 trials","volume":"248","author":"Suter","year":"2025","journal-title":"Respir Med"},{"key":"B33","doi-asserted-by":"publisher","DOI":"10.1016\/j.chest.2024.09.049","article-title":"The emerging role of alarmin-targeting biologics in the treatment of patients with COPD","volume":"167","author":"Celli","year":"2025","journal-title":"Chest"},{"key":"B34","doi-asserted-by":"publisher","DOI":"10.2147\/jir.s552274","article-title":"Established and emerging biological therapies for the treatment of comorbid asthma and chronic obstructive pulmonary disease","volume":"18","author":"Cazzola","year":"2025","journal-title":"J Inflammation Res"},{"key":"B35","doi-asserted-by":"publisher","DOI":"10.1126\/scitranslmed.adu3759","article-title":"The IL-33 and IL-4R\u03b1 blocking antibodies itepekimab and dupilumab modulate both distinct and common inflammatory mediators in asthma","volume":"17","author":"Asrat","year":"2025","journal-title":"Sci Transl Med"},{"key":"B36","doi-asserted-by":"publisher","DOI":"10.1183\/13993003.congress-2025.pa4574","article-title":"The number needed to treat with dupilumab to prevent moderate or severe chronic obstructive pulmonary disease exacerbations: BOREAS and NOTUS","volume":"66","author":"Bhatt","year":"2025","journal-title":"Eur Respir J"},{"key":"B37","doi-asserted-by":"publisher","DOI":"10.1056\/nejmoa2406673","article-title":"Twice-yearly depemokimab in severe asthma with an eosinophilic phenotype","volume":"391","author":"Jackson","year":"2024","journal-title":"N Engl J Med"},{"key":"B38","doi-asserted-by":"publisher","DOI":"10.1039\/d5pm00230c","article-title":"Advanced bispecific antibody design and inhaled biologics; emerging strategies for asthma","volume":"3","author":"Kassem","year":"2026","journal-title":"RSC Pharmaceutics"}],"container-title":["Frontiers in Immunology"],"original-title":[],"link":[{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fimmu.2026.1906783\/full","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,9,14]],"date-time":"2026-09-14T04:35:15Z","timestamp":1789360515000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fimmu.2026.1906783\/full"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,9,14]]},"references-count":38,"alternative-id":["10.3389\/fimmu.2026.1906783"],"URL":"https:\/\/doi.org\/10.3389\/fimmu.2026.1906783","relation":{},"ISSN":["1664-3224"],"issn-type":[{"value":"1664-3224","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,9,14]]},"article-number":"1906783"}}